The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Authors
Keywords
-
Journal
Alzheimers Research & Therapy
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-07
DOI
10.1186/s13195-021-00942-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
- (2021) Joel Simrén et al. Alzheimers & Dementia
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
- (2021) Pratishtha Chatterjee et al. Translational Psychiatry
- Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
- (2021) Nicholas J. Ashton et al. ACTA NEUROPATHOLOGICA
- The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
- (2021) N. J. Ashton et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
- (2021) Niklas Mattsson‐Carlgren et al. EMBO Molecular Medicine
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
- (2021) Tim West et al. Molecular Neurodegeneration
- Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
- (2021) Claudia Cicognola et al. Alzheimers Research & Therapy
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
- (2021) Sarah K. Royse et al. Alzheimers Research & Therapy
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
- (2021) Shorena Janelidze et al. Alzheimers & Dementia
- A multicentre validation study of the diagnostic value of plasma neurofilament light
- (2021) Nicholas J. Ashton et al. Nature Communications
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
- (2021) Andréa L. Benedet et al. JAMA Neurology
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
- (2020) Elisabeth H. Thijssen et al. NATURE MEDICINE
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
- (2020) Juan Lantero Rodriguez et al. ACTA NEUROPATHOLOGICA
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- (2020) Sebastian Palmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial
- (2020) Lauri Wihersaari et al. INTENSIVE CARE MEDICINE
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
- (2020) Thomas K. Karikari et al. MOLECULAR PSYCHIATRY
- Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
- (2020) Inge M. W. Verberk et al. Alzheimers Research & Therapy
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
- (2019) Oliver Preische et al. NATURE MEDICINE
- Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
- (2019) Nicholas J. Ashton et al. Acta Neuropathologica Communications
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
- (2019) Suzanne E. Schindler et al. NEUROLOGY
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
- (2017) Niklas Mattsson et al. JAMA Neurology
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Plasma β-amyloid in Alzheimer’s disease and vascular disease
- (2016) Shorena Janelidze et al. Scientific Reports
- Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid
- (2013) Susan M. Landau et al. ANNALS OF NEUROLOGY
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization
- (2009) R. C. Petersen et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now